Trials / Completed
CompletedNCT00855738
A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and topiramate, used as first-choice combination therapy (bitherapy) in patients with focal epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide | * Gabapentin: up to 3.600 mg/d * Lamotrigine: up to 400 mg/d * Levetiracetam: up to 3.000 mg/d * Pregabalin: up to 600 mg/d * Oxcarbazepine: up to 2.400 mg/d * Tiagabine: up to 30 mg/d * Topiramate: up to 400 mg/d * Zonisamide: up to 500 mg/d |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2009-03-04
- Last updated
- 2021-01-25
- Results posted
- 2010-07-23
Source: ClinicalTrials.gov record NCT00855738. Inclusion in this directory is not an endorsement.